Results 121 to 130 of about 145,320 (184)

Anti-PLA2R antibody positivity in adult minimal change disease with tuberculosis co-infection: A case report. [PDF]

Medicine (Baltimore)
Chen X, Li N, Yang Q, Ling H, Yin H.
europepmc   +1 more source

B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China. [PDF]

Front Immunol
Xu Y, Wang L, Jiang C, Sun D, Yang M, Liu J, Liu X, Wan C, Liu C, Zhang B, Bi G, Chen L, Zhang L, Lu G, Zhang L, Zhou H, Zhang X, Zhou G, Lu F, Zhang C, Sun B, Zeng M, Bian S, Zhang L, Wang N, Shen L, Yuan Y, Xing C, Mao H.   +28 more
europepmc   +1 more source

A Novel Fully Human Antitumor ImmunoRNase Targeting ErbB2-Positive Tumors

, 2010
A second generation anti-ErbB2 ImmunoRNase, called Erb-hcAb-RNase, was obtained by the fusion of Erb-hcAb, a human compact anti-ErbB2 antibody, with human pancreatic ribonuclease (HP-RNase or RNase 1).
Borriello, Marianna
core  

Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies. [PDF]

Front Immunol
Wang M, Chen L, Yan BJ, Wang JY, Liu L, Cui Z, Zhao MH.   +6 more
europepmc   +1 more source

Analysis of the correlation between serum anti-PLA2R antibodies and thromboembolic events in patients with idiopathic membranous nephropathy

Linchuang shenzangbing zazhi
ObjectiveTo investigate the correlation between serum anti-phospholipase A2 receptor antibodies （a-PLA2R Ab） level and thromboembolic events in patients with idiopathic membranous nephropathy （IMN）.MethodsA total of 279 patients diagnosed with IMN in Handan Central Hospital from January 1， 2020 to May 31， 2022 were included.
Sun Miao-xin, Wang Ding-ding, Wu Hao-wen, Cai Pan-pan, Xin Ye, Zhao Xin-cheng, Chai Wen-xiu, Li Yun-xia, Li Zi-wei, Duan Li-ping   +9 more
openaire   +1 more source

The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. [PDF]

Ann Med
Li X, Zhang Y, Xu C, Ke B.
europepmc   +1 more source

Early kinetics of anti-PLA2R-IgG4 predicts rituximab response in membranous nephropathy: a prospective biomarker study. [PDF]

Sci Rep
Chen S, Bian Y, Jia Y, Sun J, Fu R, Zhang Y, He Z, Du X.   +7 more
europepmc   +1 more source

Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report. [PDF]

Front Immunol
Guo J, Zhong A, Wu D, Liu Y, Chen Y, Xu Y, Xu R, Wan Q.   +7 more
europepmc   +1 more source

Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report. [PDF]

BMC Nephrol
Yang R, Zhu H, Luo Z, He T, Jiang M, Zhang Y, Wang T.   +6 more
europepmc   +1 more source

Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy. [PDF]

Front Immunol
Zhou J, Ai S, Zhang X, Wang X, Chen G, Wang Y.   +5 more
europepmc   +1 more source